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 ABSTRACT 
Very small superparamagnetic iron oxide nanoparticles (VSOPs) rapidly accumulate
in atherosclerotic lesions, thereby enabling plaque visualization by magnetic
resonance imaging (MRI). This study was performed to identify the uptake
mechanisms of VSOPs into atherosclerotic plaques. Low-density lipoprotein 
receptor-deficient (LDLR−/−) mice with advanced atherosclerosis were analyzed 
using MRI and transmission electron microscopy (TEM) at various time points
after intravenous administration of VSOPs. Post-mortem MRI detected VSOP 
labeling of atherosclerotic plaques 10 min after injection, and the signal increased
over the first 3 h. TEM revealed that the intensive plaque labeling was mediated by
accelerated transcytosis of VSOPs through endothelial cells overlaying atheros-
clerotic lesions. Experiments with endocytosis inhibitors and small interfering 
RNA (siRNA) revealed a dynamin-dependent mechanism involving both 
clathrin- and caveolin-mediated processes. In cell culture experiments, endothelial
VSOP uptake was enhanced under proatherogenic flow and TNFα stimulation,
conditions that are both present in plaque areas. Our study demonstrates that
VSOPs enable non-invasive MRI assessment of accelerated endothelial transcytosis, 
an important pathomechanism in atherosclerotic plaque formation. 
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1 Introduction 
Atherosclerosis is the leading cause of death in 
human society [1]. Endothelial dysfunction promotes 
extravasation of lipids and leucocytes, proliferation 
of smooth muscle cells, and finally the formation of 
atherosclerotic plaques [2, 3]. Decreased endothelial 
barrier function is a risk factor for plaque destabilization 
and rupture, with potentially life-threatening com-
plications [4, 5]. Noninvasive identification of unstable 
plaques prior to rupture is of great clinical importance 
[5]. Magnetic resonance imaging (MRI) with target- 
specific contrast agents enables visualization of specific 
structures and processes in atherosclerotic plaques [6]. 
Whereas gadolinium-based contrast agents have been 
used for visualization of extracellular matrix com-
ponents and endothelial permeability [7–10], super-
paramagnetic iron oxide nanoparticles (SPIOs) have 
been shown to label plaque macrophages as markers 
of inflammation [11, 12]. The strongest and fastest 
plaque labeling has been achieved with a certain type 
of SPIOs, so-called very small superparamagnetic iron 
oxide nanoparticles (VSOPs) [13–15]. Compared to 
conventional polymer-coated SPIOs, VSOPs are signi-
ficantly smaller (7 nm) and coated with monomeric 
citrate, and they are thereby stabilized electrostatically 
[13]. In vitro experiments in THP-1 monocytic cells de-
monstrated that the rapid cellular VSOP uptake depends 
on an interaction with cell surface glycosaminoglycans 
(GAGs) [15]. In vivo MRI studies in apolipoprotein 
E-deficient (ApoE−/−) mice revealed an increasing 
uptake of VSOPs into atherosclerotic lesions over the 
course of disease progression and identified plaque 
macrophages as imaging targets [16, 17]. Plaque 
analyses in atherosclerotic rabbits confirmed VSOP 
accumulation in macrophages and uncovered GAG- 
containing microvesicles as additional imaging targets 
[18]. In agreement with these instability-associated 
targets, the loss of MRI signal caused by VSOPs was 
reported to correlate with histological plaque instabi-
lity criteria [18]. Recently, a study comparing VSOP 
variants stabilized with different monomeric organic 
acids detected VSOP-filled vesicular structures in the 
cytoplasm of plaque endothelial cells (ECs) 3 h after 
VSOP injection [17]. This observation adds an impor-
tant new aspect to the discussion on potential VSOP 
uptake mechanisms. Although several studies have 
analyzed the imaging potential and target structures 
of VSOPs, the mechanisms underlying their rapid 
and strong accumulation in plaques remain unknown. 
Several pathways have been discussed, including 
uptake by blood monocytes with subsequent migration 
of labeled cells into the plaque, extravasation via leaky 
neovessels, and transport through plaque endothelium 
with decreased barrier function [19]. Decreased barrier 
function comprises intercellular pathways such as 
widening of tight junctions and partial or complete 
denudation, as well as transcellular pathways such as 
transcytosis [2, 20, 21]. The present study investigates 
the uptake mechanisms of VSOPs into atherosclerotic 
plaques of low-density lipoprotein receptor-deficient 
(LDLR−/−) mice. VSOP-based MRI was correlated with 
electron microscopic analyses of VSOP uptake into 
plaques at various time points after VSOP injection. 
2 Results and discussion  
2.1 MRI analyses of VSOP accumulation in 
atherosclerotic plaques 
The uptake mechanisms underlying the rapid 
accumulation of VSOPs in plaques were analyzed by 
combining MRI and transmission electron microscopy 
(TEM) in LDLR−/− mice with advanced atherosclerosis. 
We recorded T2*-weighted in situ and ex vivo MRI 
scans of the thoracic aorta at time points ranging 
from 10 min to 24 h after intravenous injection of 
VSOPs. VSOPs are rapidly cleared from the blood, 
mainly by liver and spleen, with a blood half-life of 
around 30 min [17], indicating that early time points 
after injection are the most important for uptake 
analyses. In vivo MR imaging of VSOP accumulation 
in plaques is difficult within the first two blood half- 
lives, since during that period the high intravascular 
VSOP concentration has a strong T2* effect that 
prevents adequate visualization of the vessel wall 
[22]. Furthermore, high-resolution three-dimensional 
(3D) MR imaging of the aorta takes about 30 min, 
which prohibits analyses of clearly defined time points 
in vivo. Therefore, we chose a post-mortem in situ 
approach to visualize sites of VSOP accumulation in 
the anatomical context and combined it with ex vivo  
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scans that allowed quantification of the MRI signal 
in plaques at defined time points after particle 
injection. Administration of VSOPs caused significant 
signal loss within atherosclerotic plaques that were 
present at typical predilection sites such as the aortic 
root, the inner curvature of the aortic arch, and the 
brachiocephalic trunk (Figs. 1(a) and 1(b)). Cross- 
sections of the aorta confirmed that signal extinctions 
caused by VSOPs were clearly located within atheros-
clerotic plaques in the vessel wall (Fig. 1(c)). No signal 
decay was observed in non-plaque areas of the vessel 
wall. In ex vivo scans, VSOP signals within plaques 
were clearly distinguishable from signal extinctions 
at the outside of the aorta that were caused by air 
bubbles generated during the agarose embedding 
process (Figs. 1(b) and 1(c)). 
 
Figure 1 T2*-weighted magnetic resonance imaging scans of the thoracic aorta of low-density lipoprotein receptor-deficient 
(LDLR−/−) mice at various time points after very small superparamagnetic iron oxide nanoparticle (VSOP) injection (300 µmol·kg−1). 
(a) Post-mortem in situ MRI of the ascending aorta and aortic arch 3 h after VSOP injection. (b) Ex vivo MRI of the ascending aorta 
and aortic arch 3 h after VSOP injection. VSOP accumulation caused significant signal extinctions within atherosclerotic plaques (white
arrows). Signal extinctions outside the aorta resemble air bubbles originating from agarose embedding (black arrows). (c) Examples of 
T2*-weighted in situ and ex vivo MRI cross-sections of the ascending aorta at the indicated time points after VSOP injection. VSOP
deposits within atherosclerotic lesions are clearly discernable as signal extinctions in the vessel wall. (d) Quantification of VSOP uptake 
into aortic plaques of LDLR−/− mice at various time points after VSOP injection. The percentage of dark voxels in the vessel wall was 
determined in five consecutive ex vivo MRI cross-sections of the ascending aorta for each time point (data expressed as mean ± standard 
deviation (SD)). VSOP accumulation in plaques was detectable by post-mortem MRI as early as 10 min after injection, with increasing 
signal intensities over the first 3 h and a slight decrease toward 24 h. 
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For semiquantitative analyses of VSOP uptake 
into plaques of the ascending aorta, the number of 
dark voxels was determined in 5 ex vivo aortic MRI 
cross-sections per animal. To minimize the influence 
of varying plaque size among the animals on quantifi-
cation, we calculated the percentage of dark voxels  
as a proportion of all vessel wall voxels (Fig. 1(d)). 
Quantification revealed that VSOP accumulation in 
atherosclerotic lesions of LDLR−/− mice was detectable 
by MRI as early as 10 min after injection, with 
increasing signal intensities over the first 3 h. These 
results demonstrate that VSOPs were rapidly taken 
up into atherosclerotic lesions of LDLR−/− mice, 
causing clear MRI signals within plaques 10 min after 
injection. It must be pointed out that the results 
obtained from this ex vivo approach do not allow 
conclusions to be made regarding the in vivo imaging 
characteristics of VSOPs. Future experiments will be 
necessary to assess the optimal time frame for in vivo 
imaging. 
2.2 Analyses of the mechanisms of VSOP uptake 
into atherosclerotic plaques 
Extensive TEM analysis of aortic cross-sections of 
VSOP-treated LDLR−/− mice allowed detailed inves-
tigation of VSOP uptake and accumulation in 
atherosclerotic plaques between 10 min and 24 h after 
injection (Fig. 2). For this approach, an appropriate 
fixation of atherosclerotic arteries for TEM was critical 
to preserve the ultrastructure of the inhomogeneous 
and lipid-rich plaques and to avoid artificial injury  
of the diseased endothelium. In a series of pre-tests, 
we observed a strong correlation between the extent 
of endothelial damage and the time from animal 
euthanasia to fixation. The best results with minimal 
artificial destruction of the vessel structure were 
achieved by direct transcardiac pressure-perfusion 
with a TEM-optimized fixation solution (see methods).  
In the ascending aortas of animals that were analyzed 
within 1 h after injection, numerous small VSOP 
aggregates consisting of 3–15 individual nanoparticles 
were detectable in close proximity to the plaque 
endothelial surface (Figs. 2(a)–2(c)). Moreover, we 
frequently observed flask-shaped membrane invagina-
tions with diameters of 50–80 nm filled with VSOPs 
at the luminal site of the endothelium (Figs. 2(d)–2(f)). 
VSOP-containing invaginations subsequently fully 
engulfed the nanoparticles and formed small vesicles 
after scission from the plasma membrane (Fig. 2(g)). 
At 10 min after injection, small VSOP-filled vesicles 
were already visible in the cytoplasm, and they later 
fused to form larger vesicles containing hundreds  
of nanoparticles (Figs. 2(h) and 2(i)). Eventually, 
VSOP aggregates appeared in the subendothelial 
space (Figs. 2(j)–2(l)). Based on these observations, we 
concluded that VSOPs were delivered across ECs via 
transcytosis. 
It was previously suggested that VSOP-labeled 
blood-born monocytes are recruited into inflamed 
atherosclerotic areas of ApoE−/− mice, since macrophages 
have been identified as the main site of VSOP accu-
mulation within plaques [16]. Our TEM analysis 
revealed that VSOPs were indeed rapidly and efficiently 
taken up by peripheral blood mononuclear cells 
(PBMCs) in the circulation of LDLR−/− mice (Figs. 3(a) 
and 3(b)). Considerable amounts of internalized VSOPs 
were already detectable in murine PBMCs at 10 min 
after injection. PBMC-associated VSOPs were mainly 
located in vesicles with diameters of 100–250 nm, each 
containing hundreds of VSOPs (Fig. 3(a)). A decrease 
in the number of circulating VSOP-positive PBMCs 
was measured 3 h after injection. Although we did not 
observe any transmigration of VSOP-labeled PBMCs 
into atherosclerotic plaques by TEM, this uptake 
mechanism cannot be ruled out. Since considerable 
numbers of circulating VSOP-loaded PBMCs were 
persistently detectable up to 7 d after injection    
(Fig. 3(b)), it is conceivable that these cells may 
gradually contribute to the labeling of atherosclerotic 
lesions with superparamagnetic iron. In contrast to 
PBMCs, VSOPs were not detected in red blood cells 
(RBCs) isolated from VSOP-injected LDLR−/− mice 
(Fig. 3(c)). In addition, we compared the uptake of 
VSOPs into isolated PBMCs and RBCs in vitro using 
the highly sensitive superparamagnetic nanoparticle- 
specific magnetic particle spectroscopy (MPS). As 
shown in Table 1, superparamagnetic iron was already 
detectable inside PBMCs after 10 min of incubation 
with 0.75 mM VSOPs, and the intracellular concen-
tration increased with longer incubation time. In 
contrast, the superparamagnetic iron content in RBC 
samples was below the detection limit of MPS (limit 
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of detection = 91 ng), even after 1 h of incubation 
with VSOPs (Table 1). Since RBCs are incapable of 
endocytosis [23], we concluded that the cellular uptake 
of VSOPs strictly depends on endocytic processes. 
Passive membrane penetration as an uptake mechanism 
for VSOPs is not supported by our data.  
In our detailed TEM studies, we did not observe the 
passage of VSOPs via intercellular pathways through 
interendothelial junctions (IEJs) or regions of endothelial 
denudation. Having a hydrodynamic diameter of 
8.7–11 nm, VSOPs are too large to pass through intact 
IEJs. Interestingly, the frequent occurrence of widened 
IEJs, as reported for ApoE−/− mice with advanced 
atherosclerosis, could not be confirmed in our exper-
imental setup using the present fixation protocol [10]. 
Areas of endothelial denudation with exposure of 
subendothelial structures were rarely observed, and no 
VSOP accumulation was detectable in these regions. 
 
Figure 2 TEM analyses of VSOP uptake into aortic atherosclerotic lesions of LDLR−/− mice 10 min to 24 h after injection. VSOPs 
are visible as electron-dense spots with diameters of ~7 nm (arrows). (a) Initial binding of small VSOP aggregates to the luminal surface 
of ECs. (b) and (c) VSOPs associated with invaginations of the plasma membrane. (d)–(f) Endocytic pits containing nanoparticles. 
(g) Scission of a VSOP-containing pit from the plasma membrane. (h) and (i) Fusion of small VSOP-filled vesicles to larger vesicles. 
(j)–(l) VSOP aggregates in the subendothelial space of atherosclerotic lesions. Time after injection: (a)–(e) 10 min; (f)–(h) 30 min; (i) 3 h;
(j)–(l) 24 h. Scale bars: (a)–(i) 50 nm; (j)–(l) 100 nm. VL—vascular lumen, EC—endothelial cells, SE—subendothelial space. 
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Table 1 Comparison of VSOP uptake into peripheral blood 







0 n.d.d n.d.d 
10 min 0.62 ± 0.10 n.d.d 
30 min 1.17 ± 0.12 n.d.d 
1 h 1.34 ± 0.07 n.d.d 
aPBMCs = peripheral blood mononuclear cells isolated from 
LDLR−/− mice; bRBCs = red blood cells isolated from LDLR−/− 
mice; ccFeMPS = concentration of superparamagnetic iron measured 
by magnetic particle spectroscopy; data are expressed as mean ± 
standard deviation, n = 3, dn.d. = non-detectable. 
 
Therefore, we assumed that the observed denudation 
probably occurred artificially during the preparation 
procedure.  
In our experiments, we did not observe neovessels 
within plaques of LDLR−/− mice. Neovascularization 
mediated by hypoxia occurs when the tunica intima  
thickens to a width of above 500 μm [24]. Hence, the 
shorter diffusion distances in mouse plaques compared 
to those in human plaques may explain the absence 
of neovessels in our model. The extravasation of VSOPs 
via neovessels in humans or other species cannot be 
excluded by our study. However, rapid and efficient 
plaque labeling with VSOPs obviously does not depend 
on the presence of neovessels. 
We concluded that uptake by blood monocytes with 
subsequent migration of labeled cells into the plaque, 
transport via intercellular pathways, and delivery via 
neovessels do not considerably account for the rapid 
VSOP enrichment in plaques that enables MRI within 
1 h after injection. Our current data provide evidence 
for endothelial transcytosis as the main uptake 
mechanism of VSOPs into atherosclerotic plaques of 
LDLR−/− mice.  
In a following step, we investigated the endocytic 
mechanisms mediating VSOP uptake into ECs in 
greater detail by performing in vitro experiments with  
 
Figure 3 TEM analyses of in vivo VSOP uptake into peripheral blood mononuclear cells (PBMCs) and red blood cells (RBCs) of 
LDLR−/− mice. (a) PBMC with a VSOP-filled cytoplasmic vesicle 3 h after VSOP injection (arrow). (b) Percentage of VSOP-positive 
PBMCs determined by TEM analyses of ≥100 PBMCs for each time point after injection. The percentage of VSOP-positive PBMCs
remained at high levels up to 3 h after injection. Even at 7 d after injection, VSOP-positive PBMCs were still detectable. (c) RBCs 
isolated from LDLR−/− mice 3 h after VSOP injection did not contain VSOPs. Scale bars: (a) 100 nm; (c) 1 µm. 
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human umbilical vein ECs (HUVECs). First, HUVECs 
were treated with dynasore, a specific inhibitor of  
the GTPase dynamin, which is essential for scission 
of newly formed endocytic vesicles from the plasma 
membrane in clathrin- and caveolin-dependent endo-
cytosis [25]. We used dynasore at concentrations of 
75 and 150 μM, which were sufficient to inhibit the 
internalization of fluorescence-labeled bovine serum 
albumin (BSA) and human transferrin (hTF), both  
of which are well-established markers for dynamin- 
dependent endocytic processes (Fig. 4(a)). The efficient 
uptake of VSOPs into HUVECs was significantly 
 
Figure 4 VSOP uptake is dynamin-dependent and involves clathrin- and caveolin-mediated processes. (a) HUVECs were grown on 
chambered coverslips. After pretreatment with vehicle (upper panel) or 75 µM dynasore for 30 min to inhibit dynamin function (lower 
panel), cells were incubated with Texas Red-labeled bovine serum albumin (BSA), Fluorescein isothiocyanate (FITC)-labeled human 
transferrin (hTF), or VSOPs for 60 min. Internalized BSA-Texas Red and hTF-FITC were visualized by fluorescence microscopy, 
VSOPs were visualized by light microscopy after Prussian blue staining. (b) Quantification of VSOP uptake into HUVECs after 
pretreatment with 75 and 150 µM dynasore by measurement of the Prussian blue-stained area per cell compared with that of vehicle-
treated controls. (c) Immunoblots showing clathrin heavy chain (CLT) and caveolin-1 protein (CAV-1) levels after knockdown with 
siRNA in HUVECs and quantification of VSOP uptake into HUVECs after knockdown of CLT and CAV-1 compared with control 
siRNA (SCR). Amido black staining of immunoblot membranes served as a control for equal protein loading (LC). Data are presented 
as mean ± SD, n = 3 experiments. (d) TEM image of an aortic plaque EC of a VSOP-injected LDLR−/− mouse after post-contrasting 
with uranyl acetate and lead citrate showing VSOPs (arrows) associated with a clathrin-coated pit (CCP) and a caveolae-like structure 
(CAV). Scale bars: (a) 10 μm; (d) 100 nm. 
  | www.editorialmanager.com/nare/default.asp 
3444 Nano Res. 2016, 9(11): 3437–3452
inhibited by dynasore (Figs. 4(a) and 4(b)). Knockdown 
of caveolin-1 (CAV-1) or clathrin heavy chain protein 
(CLT) with small interfering RNA (siRNA) in HUVECs 
resulted in decreased VSOP uptake (Fig. 4(c)). These 
experimental data indicate that VSOP uptake into 
ECs is dynamin-dependent, involving both caveolin- 
and clathrin-mediated processes. We verified the 
existence of VSOP-engulfing clathrin-coated pits 
and caveolae in the endothelium of LDLR−/− mice by 
TEM analyses of post-contrasted aortic cross-sections 
(Fig. 4(d)). 
2.3 Comparison of VSOP uptake into plaque and 
non-plaque ECs 
Figure 5(a) shows the characteristic histology of aortic 
arch cross-sections of LDLR−/− mice. Due to flow 
conditions, atherosclerotic lesions were mainly located 
in the inner curvature of the aortic arch, whereas the 
outer curvature exhibited mostly non-diseased vessel 
wall. During TEM analyses, we differentiated between 
plaque ECs and non-plaque ECs based on their 
morphologies: ECs covering subendothelial foam cells 
and extracellular matrix deposits were defined as 
plaque ECs (Fig. 5(b)), whereas ECs covering vessel 
areas with intact subendothelial layers including the 
internal elastic lamina and basement membrane were 
defined as non-plaque ECs (Fig. 5(c)). We analyzed 
200 plaque ECs and 200 non-plaque ECs at each time 
point after VSOP injection. As depicted in Fig. 5(d), 
the percentage of VSOP-positive ECs and the number 
of VSOP-filled vesicles per EC were significantly 
higher in plaque ECs than in non-plaque ECs at all 
time points and reached a maximum at 30 min after 
injection (paired t-test, p < 0.01). The lower number  
of VSOP-filled vesicles at later time points can be 
explained by the decreased plasma concentration of 
VSOPs, which minimized further uptake from the 
vessel lumen, the fusion of small vesicles to larger 
vesicles in the cytoplasm of ECs, and the subsequent 
release of VSOPs into the subendothelial space. 
Accumulations of VSOPs in subendothelial areas 
and foam cells were exclusively observed in atheros-
clerotic lesions. Our TEM analyses demonstrate that 
the specific enrichment of VSOPs in atherosclerotic 
lesions is attributed to an increased transcytosis of 
nanoparticles through plaque ECs. Thus, early 
signals in VSOP-based MRI reflect the increase   
in endothelial transcytosis within atherosclerotic 
plaques.  
Visualization of increased endothelial permeability 
is of great clinical relevance, e.g., for the detection of 
unstable plaques and for the monitoring of interventions 
that aim to restore the endothelium. Several imaging 
studies with various contrast agents, e.g., albumin- 
binding gadofosveset and fluorescence-labeled liposomal 
nanoparticles, have suggested that increased endothelial 
permeability is important for agent uptake and plaque 
visualization [10, 26]. Increased endothelial permeability 
is a collective term that comprises several mechanisms, 
including the widening of IEJs, gap formation, erosion 
and denudation, and various types of vesicular 
transcytosis. To the best of our knowledge, we are the 
first to describe accelerated endothelial transcytosis 
within atherosclerotic plaques as an imaging target 
for MRI. Most importantly, accelerated endothelial 
transcytosis is an important pathomechanism that  
is considered to be a major route for low-density 
lipoprotein (LDL) uptake into atherosclerotic plaques 
[27, 28].  
2.4 Evaluation of processes that accelerate 
endocytosis of VSOPs into ECs 
Endothelial function is substantially determined by 
the continuous apical shear forces produced by 
flowing blood. Disturbed laminar blood flow in vessel 
curves and bifurcations contributes to endothelial 
dysfunction that accelerates atherogenesis at these 
sites [29]. We tested the hypothesis that flow conditions 
modulate the uptake of VSOPs into cultivated HUVECs. 
As expected, laminar flow altered cell morphology: 
HUVECs cultivated under laminar flow were aligned 
parallel to the direction of the flow, while cells 
cultivated in the absence of laminar flow were diffusely 
distributed (Fig. 6(a)). HUVECs cultivated under 
laminar flow conditions only marginally internalized 
VSOPs (Figs. 6(a) and 6(b)). Stimulation with tumor 
necrosis factor (TNF)α caused a significant increase of 
VSOP uptake into HUVEC cultivated under laminar 
flow (25-fold higher than in non-stimulated HUVECs) 
(Figs. 6(a) and 6(b)). Remarkably, VSOP uptake was   
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exceedingly high in HUVECs maintained under 
static conditions (48-fold higher than in HUVECs 
under laminar flow) (Figs. 6(a) and 6(b)). To study 
the differential effects of uniform laminar flow and 
disturbed flow on VSOP uptake, HUVECs were 
exposed to laminar flow in Y-shaped channels, which 
mimic the shear-stress conditions present at arterial 
bifurcations. HUVECs exposed to disturbed flow, as 
present at the branch and kink regions, showed a 
strongly increased uptake of VSOPs compared to cells 
exposed to uniform laminar shear stress, as present 
at the straight segments (Figs. 6(c) and 6(d)). 
These results demonstrate that inflammation and 
disturbed laminar flow, two factors that play major 
roles in endothelial dysfunction, contribute to the 
accelerated endocytosis of VSOPs into the plaque 
endothelium.  
As a possible mechanism, we considered the 
 
Figure 5 Comparison of VSOP uptake into plaque and non-plaque ECs of LDLR−/− mice. (a) Toluidine-blue stained semithin section 
(500 nm) of the aorta of an LDLR−/− mouse with an advanced-stage atherosclerotic plaque in the inner curvature of the aortic arch. (b) TEM
image of a plaque EC covering foam cells and extracellular matrix deposits. VSOPs are indicated by arrows. (c) TEM image of a
non-plaque EC with intact subendothelial layers. (d) The percentage of VSOP-positive ECs and the average number of vesicles per EC 
were significantly higher in plaque ECs than in non-plaque ECs at all time points. Data were acquired by TEM analyses of 200 plaque
ECs and 200 non-plaque ECs for each time point after injection. Scale bars: (a) 100 µm; (b) and (c) 1,000 nm. VL—vascular lumen, 
EC—endothelial cells, SE—subendothelial space, IEL—internal elastic lamina. 
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modulation of the glycocalyx of pathologically altered 
ECs. Indeed, TEM images of VSOP uptake into ECs 
in vivo showed that VSOPs initially do not bind directly 
to the EC membrane (Figs. 2(a) and 2(b)), but rather  
to the cell surface glycocalyx, a mesh of membrane- 
associated GAGs [30]. The high affinity of VSOPs  
to GAGs was reported in recent in vivo and in vitro 
studies [15, 18]. We hypothesized that the VSOP–GAG 
interaction occurs in a transchelation reaction in which 
the citrate coat of the cationic iron oxide core of the 
VSOPs is replaced by a GAG coat. This hypothesis 
was supported by the observation that the magnetic 
properties of VSOPs change immediately after contact 
with cells [31]. Considering that an electrostatic 
interaction with cell surface GAGs and subsequent 
endocytosis of the resulting complexes have been 
reported for polycationic macromolecules and cationic 
peptides [32], and for phagocytosis of VSOPs into 
macrophages [15], we propose a similar mechanism 
for the uptake of VSOPs into the endothelium. It 
must be considered that, after injection, nanoparticles 
adsorb a so-called biomolecule corona, which is a 
dynamic layer of proteins, lipids, and carbohydrates. 
A recent study showed that the GAG hyaluronan 
 
Figure 6 Effects of shear forces and pro-inflammatory stimulation on VSOP uptake into HUVECs. (a) Confluent cells grown on 
IbiTreat µ-slides I 0.8 Luer were exposed to laminar flow (LF) for 72 h with or without stimulation with 5 ng·mL−1 TNF-α (LF and LF + 
TNF), or were grown under static conditions before the application of VSOPs for 3 h under LF. Nuclear fast red staining (NFR) revealed
the typical parallel alignment of HUVECs to the direction of LF. VSOPs were detected by light microscopy after Prussian blue staining 
(arrows). (b) Quantification of VSOP uptake into HUVECs grown under LF, LF + TNF, and under static conditions by determination of
the percentage Prussian blue stained area per region of interest (ROI). Data are presented as mean ± SD; n = 7 experiments, 6 ROI per 
treatment for each experiment. (c) Confluent HUVECs grown on IbiTreat µ-slides Y-shaped were exposed to LF for 48 h before the 
application of VSOPs for 3 h under LF. Arrows indicate the direction of LF. VSOPs were detected by light microscopy after Prussian 
blue staining. Cell nuclei were visualized by NFR. (d) Quantification of VSOP uptake into HUVECs grown in areas with uniform
laminar shear stress (straight segments) or in areas with disturbed flow (branch regions and kink regions) by determination of the 
percentage Prussian blue-stained area per ROI. Data are presented as mean ± SD; n = 3 experiments, 6 ROI per area (straight, branch, 
and kink) for each experiment. Scale bars: (a) and (c), 20 µm. 
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exhibits an exceptionally strong affinity toward citrate- 
coated gold nanoparticles, which allows for effective 
competition with other serum proteins for adsorption 
to the gold nanoparticles [33]. The preferential binding 
of citrate-coated VSOPs to GAGs can therefore be 
expected, although it is probable that a considerable 
part of the nanoparticles initially interacts with other 
biomolecules in the blood. 
It has previously been shown that inflammatory 
stimuli and disturbed laminar blood flow induce 
changes of the glycocalyx, not only by altering gene 
expression in ECs but also by modifying the 3D 
arrangement of proteoglycans and their associated 
GAGs on the EC surface [34, 35]. Shear forces can 
influence the ability of the glycocalyx to recognize 
and retain extracellular ligands, since the conformation 
of the glycocalyx determines the accessibility of 
extracellular ligands to their binding partners on the 
cell surface [36]. To date, only a few studies have 
investigated the influence of flow on nanoparticle 
uptake into ECs [37–39]. Whether the uptake is inhibited 
[38] or enhanced [37] in response to laminar flow most 
probably depends on the binding partner on the cell 
surface and on the size and charge of the particles [40].  
3 Conclusion 
This study provides further evidence for the potential 
of VSOP for rapidly visualizing atherosclerotic lesions. 
We describe here for the first time the uptake process 
of VSOPs into atherosclerotic plaques. The rapid and 
efficient uptake of VSOPs is mediated by accelerated 
dynamin-dependent transcytosis through plaque  
ECs. Inflammation and disturbed laminar flow were 
identified as causes of the accelerated transcytosis. 
With these characteristics, VSOPs enable the non- 
invasive MRI assessment of increased endothelial 
transcytosis, an important pathomechanism in 
atherogenesis.  
4 Methods 
4.1 Synthesis of VSOPs 
Chemicals and solvents were obtained from Sigma- 
Aldrich, St. Louis, MO, unless otherwise stated. For 
the synthesis of citrate-coated iron oxide nanoparticles, 
14 g ferrous chloride tetrahydrate and 24.7 g ferric 
chloride hexahydrate were each dissolved in 100 mL 
deoxygenated H2Obidest at 2 °C and then combined. To 
this solution, 90 mL of 28% ammonium hydroxide 
cooled to 2 °C was quickly added. The mixture was 
stirred for 1 h at 2 °C and magnetically sedimented 
(0.5 T). The supernatant was withdrawn and the 
sediment was dispersed with 300 mL 0.348 M citric 
acid. This mixture was heated to 80–90 °C and stirred 
for 1 h at this temperature. After cooling to room 
temperature (RT), the mixture was again magnetically 
sedimented and the supernatant was centrifuged. 
The supernatant resulting from this centrifugation 
step was subsequently diluted and ultrafiltered 
(Vivaflow®, PES, 100 kDa) to a conductivity of the 
filtrate < 10 μS·m–1. The retentate was diluted with  
100 mL 0.25% (w/v) sodium chloride solution and 
adjusted to a pH of 5.5 with citric acid, then ultrafiltered 
again. The retentate was diluted with 100 mL H2Obidest 
and ultrafiltered. This procedure was repeated until 
the filtrate reached a conductivity < 10 μS·m−1. After 
iron quantification, the retentate was adjusted to a 
concentration of 0.15 M Fe with H2Obidest. After adjusting 
to pH 7.0 with 0.5 M disodium citrate, the solution 
was formulated with mannitol (final concentration: 
60 g·L−1). The final formulation was heat-sterilized. At 
a final iron concentration of 0.116 M, a citric acid 
concentration of 0.937 g·L−1 was measured. The mean 
hydrodynamic diameter of the nanoparticles (as 
measured by laser light scattering) was 8.7–11.0 nm 
with a polydispersity index of 0.085, indicating a 
narrow distribution. Relaxivities in water were r1 = 
25 mM−1·s−1 and r2 = 63.8 mM−1·s−1 at 0.94 T at a 
saturation magnetization of 95 emu·g−1 iron. The 
crystallite size measured by TEM (largest diameter  
of 500 crystals evaluated) was 6.8 ± 2 nm. The final 
ferrous iron ion content of 0.9% (molar ratio total iron) 
indicates nearly complete oxidation to maghemite. 
Selected area electron diffraction revealed a pure 
magnetite/maghemite pattern.  
4.2 Animals and treatments 
Animal experiments were approved by the local 
authority (Landesamt für Gesundheit und Soziales, 
Berlin) and were performed according to institutional 
  | www.editorialmanager.com/nare/default.asp 
3448 Nano Res. 2016, 9(11): 3437–3452
guidelines. Animals were kept under standard housing 
conditions and a 12 h day/night cycle with water and 
food ad libitum. A total of 14 male 10-week-old LDLR−/− 
mice (B6.129S7-Ldlrtm1Her/J; JAX Mice, Boston) were 
fed a high-fat diet for 20 weeks ad libitum (Western- 
type diet containing 21% (w/w) butterfat, 17% (w/w) 
casein, and 0.21% (w/w) cholesterol; Ssniff, Soest, 
Germany). Animals received VSOPs at a dose of  
300 μmol·kg−1 of bodyweight via tail vein injection. 
Two animals were analyzed at each of the following 
time points after VSOP injection: 10 min, 30 min, 1 h, 
3 h, 24 h, and 7 d. Two animals without VSOP injection 
served as controls. Mice were sacrificed under isoflurane 
general anesthesia as described below. For in vitro 
uptake experiments, PBMCs and RBCs were isolated 
from 3 LDLR−/− mice that were fed a normal diet. 
4.3 MRI 
For post-mortem in situ MRI analyses of the thoracic 
aorta, animals were sacrificed under isoflurane general 
anesthesia by blood withdrawal. The abdominal 
aorta was cannulated by retrograde puncture and 
the inferior vena cava was opened for drainage. To 
remove the remaining blood, perfusion was started 
with 0.9% (w/v) sodium chloride solution at 37 °C 
for 1 min. Retrograde perfusion was then performed 
using fixation solution (4% (w/v) paraformaldehyde 
and 0.05% (v/v) glutaraldehyde in 0.1 M cacodylate 
buffer (0.1 M sodium cacodylate in H2Obidest, pH 7.4; 
CB)) at RT for 5 min [41]. After in situ MRI scans,  
the ascending aorta, the aortic arch (including 
brachiocephalic trunk, left common carotid artery and 
left subclavian artery), and the descending thoracic 
aorta were prepared and embedded in 1% (w/v)  
low melting point agarose (Thermo Fisher Scientific, 
Waltham, MA) in a 15 mL Falcon® tube for ex vivo 
MRI scans.  
MRI analyses were performed on a 7 Tesla BioSpec 
70/20 USR scanner (Bruker, Billerica, MA) equipped 
with a 1H-CryoProbe coil (Bruker). First, in situ MRI 
scans of retrogradely perfused animals were recorded. 
FLASH 2D overviews were acquired with the following 
parameters: field of view (FOV) = 25 × 25 mm; repeti-
tion time (TR)/echo time (TE) = 250 ms/3.5 ms, flip 
angle (FA) = 30°, 6 averages (NEX), matrix dimension 
(MD) 256 × 256, 20 consecutive 0.3 mm thick slices, 
acquisition time (TA) = 4 min and 18 s, followed by 
FLASH 3D scans: FOV = 19.2 × 19.2 × 16 mm; TR/TE = 
36.5 ms/8 ms, FA = 20°, NEX = 2, MD 192 × 192 × 160; 
TA = 42 min and 2 s.  
To evaluate the uptake of VSOPs into atherosclerotic 
plaques at various time points after intravenous 
injection, semiquantitative analyses of MRI scans of the 
aortic arch were performed ex vivo using a FLASH 3D 
pulse sequence: FOV = 19.2 mm3, TR/TE = 31 ms/8 ms, 
FA = 20°, NEX = 1, MD 192 × 192 × 192; TA = 21 min 
and 25 s. VSOP accumulation causes signal extinctions 
in T2* sequences. Thus, dark voxels, having less than 
67% signal magnitude compared to the surrounding 
agarose, were counted in cross-sections of the 
ascending aorta to determine the percentage of dark 
voxels within the vessel wall. Five consecutive sections 
were analyzed in 1 animal per time point after 
VSOP injection. Image processing and analyses were 
performed using ImageJ (http://imagej.nih.gov/ij/). 
4.4 TEM 
Animals were sacrificed under isoflurane general 
anesthesia by blood withdrawal and subsequent per-
fusion via the left ventricle with drainage over the right 
atrium. To remove the remaining blood, perfusion 
was started with 0.9% (w/v) sodium chloride solution 
at 37 °C for 1 min at a pressure of 100 mmHg. Thereafter, 
animals were perfused with fixation solution consisting 
of 4% (w/v) paraformaldehyde and 0.05% (v/v) 
glutaraldehyde in 0.1 M CB at RT for 5 min at a 
pressure of 100 mmHg [41]. The ascending aorta,  
the aortic arch (including brachiocephalic trunk, left 
common carotid artery, and left subclavian artery), 
and the descending thoracic aorta were prepared and 
post-fixed in a solution of 4% (w/v) paraformaldehyde 
and 4% (v/v) glutaraldehyde in 0.1 M CB at pH 7.4 at 
RT for 1 h. After fixation, samples were washed in CB 
containing 0.15 M sucrose at pH 7.4 for 3 × 5 min. 
Thereafter, samples were treated with 4% (w/v) 
osmium tetroxide in H2Obidest for 60 min at RT and 
subsequently washed again in 0.1 M CB for 3 × 10 min. 
Samples were dehydrated in ethanol (70%, 80%, 90%, 
96%, and 100% (v/v); 2 × 10 min each), transferred 
into 100% propylene oxide (2 × 30 min), and embedded 
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in epoxy embedding medium according to the 
manufacturer’s instructions (Sigma-Aldrich). Resin 
was polymerized for 24 h at 60 °C. Ultrathin sections 
(60 nm) were cut using an ultramicrotome (Leica, 
Wetzlar, Germany) with a diamond knife (Diatome, 
Hatfield, PA). Ultrathin sections were collected on 
300-mesh copper grids (Plano, Lunen, Germany). TEM 
was performed on an EM 912 instrument (Carl Zeiss, 
Oberkochen, Germany) [42].  
4.5 Post-contrasting of ultrathin sections 
For better visualization of the ultrastructure, individual 
grids underwent post-contrasting. These grids were 
incubated in droplets of 2% (w/v) uranyl acetate 
(Merck, Kenilworth, NJ) in 70% (v/v) ethanol on 
Parafilm® for 2 min in the dark. Afterwards, grids 
were jet-rinsed with H2Obidest twice and air-dried 
again. Sections were post-contrasted with lead citrate 
(133 mg lead nitrate, 200 mg sodium citrate, and 80 μL 
10 N aqueous sodium hydroxide in 5 mL H2Obidest) for 
20 s, again followed by 2 jet-rinsing steps with H2Obidest 
and air-drying [42].  
4.6 Preparation of PMBCs and RBCs 
PBMCs and RBCs were isolated from the blood sample 
by density-gradient centrifugation with lympholyte-M® 
(Cedarlane, Burlington, ON, Canada). PBMCs and 
RBCs were washed with phosphate-buffered saline 
(PBS) and sedimented by centrifugation. For TEM 
analysis, the cell pellets were fixed in 4% (w/v) 
paraformaldehyde and 4% (v/v) glutaraldehyde in 
0.1 M CB at pH 7.4 at RT for 1 h and further processed 
for TEM analysis as described above. For ex vivo uptake 
studies, PBMCs and RBCs were counted and 3.35 × 105 
cells were incubated with 0.75 mM VSOPs in 100 μL 
PBS in polymerase chain reaction tubes (0.2 mL) at 
37 °C for the indicated times in duplicates. Following 
incubation, the cells were centrifuged at 1,200g for 5 min 
and washed 3 times with PBS. Total superparamagnetic 
iron content was measured by MPS.  
4.7 MPS 
MPS measurements of VSOP content in organs and 
blood were performed using a commercial magnetic  
particle spectrometer (Bruker) as previously described 
in detail [31]. VSOP calibration curves had high 
correlation coefficients (R2 = 0.99) and the limit of 
detection with a signal-to-noise ratio of 3 was assessed 
as 91 ng, reflecting the high sensitivity of this method. 
4.8 Cell culture and treatments 
HUVECs were isolated by collagenase type II (Merck) 
digestion of human umbilical veins as described pre-
viously [43]. HUVECs were cultured in EC medium 
(MCDB 131 media, Gibco®, Thermo Fisher Scientific), 
supplemented with 2% (v/v) fetal calf serum, 0.5 μL·mL−1 
basic fibroblast growth factor (Biomol, Hamburg, 
Germany), 5 U·mL−1 heparin (Merck), 0.1 ng·mL−1 
epidermal growth factor (Biomol), 1 μg·mL−1 hydro-
cortisone, 10 μL·mL−1 streptomycin (Thermo Fisher 
Scientific), 10 μL·mL−1 L-glutamine (Thermo Fisher 
Scientific), and 4 μL·mL−1 endothelial cell growth 
supplement (Promocell, Heidelberg, Germany) in a 
humidified incubator at 37 °C with 5% CO2. HUVECs 
were used until passage 5. Uptake studies under 
different flow conditions were performed using the 
ibidi unidirectional laminar flow pump system (ibidi, 
Planegg, Germany). A total of 150,000 HUVECs were 
seeded in IbiTreat μ-slides I 0.8 Luer or IbiTreat 
μ-slides Y-shaped (ibidi) and incubated overnight 
under static conditions to allow the cells to adhere 
and grow to confluence. Cell culture was continued 
under static or flow conditions (10 dyn·cm−2) for 
48 h (μ-slides Y-shaped) or 72 h (μ-slides I 0.8 Luer). 
Where indicated, cells were stimulated with 5 ng·mL−1 
TNFα for 24 h prior to VSOP administration. After 
48 or 72 h, HUVECs were incubated with 0.75 mM 
VSOPs under flow conditions (10 dyn·cm−2) for 3 h. For 
endocytosis experiments, HUVECs were plated onto 
gelatin-coated LabTek™ chambered glass coverslips 
(Nunc, Roskilde, Denmark) 6 h before the experiment. 
HUVECs that were pretreated with siRNA or dynasore 
as described below were incubated with VSOPs 
(0.15 mM) for 60 min at 37 °C in EC medium.  
4.9 Inhibition of endocytosis 
For pharmacological inhibition of endocytosis, 
HUVECs were pretreated before VSOP application 
with 75 or 150 μM dynasore (Abcam, Cambridge, UK) 
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for 30 min at 37 °C. Efficacy of inhibition was tested 
by analyzing the uptake of the fluorescently labeled 
endocytosis markers hTF (12 μg·mL−1 hTF-FITC; 
Molecular Probes, Eugene, OR) and BSA (2.5 μg·mL−1 
BSA-Texas Red; Molecular Probes) after 60 min 
incubation in EC medium by fluorescence microscopy 
using a Zeiss Axiovert microscope connected to a 
Zeiss AxioCam MrC. Knockdown of human CAV-1 
and human clathrin heavy chain (CLTC) expression 
was achieved using Silencer® Select validated siRNA 
ID: s2446 and siRNA ID: s475 (Ambion®, Thermo Fisher 
Scientific), respectively. Silencer® Select negative control 
siRNA (Thermo Fisher Scientific) served as a control. 
Cells were seeded onto 6-well plates and cultured  
for 24 h to reach 50%–60% confluency on the day of 
transfection. Oligofectamine™ (Invitrogen, Carlsbad, 
CA) was used for transfection according to the 
manufacturer’s protocol. An initial transfection was 
followed by a second transfection after 24 h. Cells 
were plated onto gelatin-coated LabTek™ chambered 
glass coverslips (Nunc) 42 h after the second trans-
fection and allowed to adhere for 6 h before VSOP 
incubation. 
4.10 Western blot analysis 
Following transfection, cells were washed twice 
with PBS and lysed in extraction buffer (50 mM 
Tris–HCl, 150 mM KCl, 5 mM glucose, 0.5 mM 
ethylenediaminetetraacetic acid pH 8.0, 0.5 mM 
phenylmethylsulfonyl fluoride, 2 mM dithiothreitol, 
and 1% (v/v) Triton™ X-100). Total protein (5 μg  
per lane) was subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis, followed by transfer 
to nitrocellulose membranes. Membranes were probed 
with anti-CAV-1 (N-20) or anti CLTC (C-20) antibodies 
(Santa Cruz Biotechnology, Dallas, TX). This was 
followed by incubation with secondary antibodies 
conjugated with horseradish peroxidase and detection 
with ECL Plus (GE Healthcare, Little Chalfont, UK). 
Amido black staining of membranes served as a control 
for equal protein loading. 
4.11 Quantification of VSOP uptake in HUVECs 
After VSOP incubation, cells were gently washed 
with PBS and fixed with 4% (w/v) paraformaldehyde 
(Roti®-Histofix 4%, Carl Roth, Karlsruhe, Germany) 
for 10 min. Cells were rinsed with PBS and stained 
with Prussian blue (2% (w/v) potassium ferrocyanide 
in 1% (v/v) HCl) for 5 min. Where indicated, staining 
with Prussian blue was followed by counterstaining 
with nuclear fast red (Carl Roth) for 5 min. After 
staining, the ibiTreat μ-slides were washed with PBS 
and filled with mounting medium for microscopy 
(Thermo Fisher Scientific). Six images per slide at 
predefined regions of interest were immediately 
acquired using a Zeiss Axiovert microscope connected 
to Zeiss AxioCam MrC. Images were analyzed using 
Zeiss AxioVision software and VSOP content was 
calculated as the percentage Prussian blue-stained 
area. For endocytosis experiments, the Prussian blue- 
stained area per cell was estimated using AxioVision 
software. The mean area per cell was averaged from 
6 regions of interest per chamber.  
4.12 Data analyses 
Data are presented as mean ± standard deviation. 
Paired Student’s t-test or one-way analysis of variance 
with Tukey’s multiple comparison test was used where 
appropriate. p-values of < 0.05 were considered to be 
statistically significant. Statistics were calculated using 
Prism 6 (GraphPad, La Jolla, CA). 
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